PT2252312E - Métodos de prevenção ou tratamento de resistência a insulina - Google Patents

Métodos de prevenção ou tratamento de resistência a insulina Download PDF

Info

Publication number
PT2252312E
PT2252312E PT97072359T PT09707235T PT2252312E PT 2252312 E PT2252312 E PT 2252312E PT 97072359 T PT97072359 T PT 97072359T PT 09707235 T PT09707235 T PT 09707235T PT 2252312 E PT2252312 E PT 2252312E
Authority
PT
Portugal
Prior art keywords
preventing
methods
insulin resistance
treating insulin
treating
Prior art date
Application number
PT97072359T
Other languages
English (en)
Inventor
Hazel H Szeto
Darrell P Neufer
Ethan J Anderson
Original Assignee
Univ Cornell
Univ East Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Cornell, Univ East Carolina filed Critical Univ Cornell
Publication of PT2252312E publication Critical patent/PT2252312E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PT97072359T 2008-02-07 2009-02-06 Métodos de prevenção ou tratamento de resistência a insulina PT2252312E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2688208P 2008-02-07 2008-02-07

Publications (1)

Publication Number Publication Date
PT2252312E true PT2252312E (pt) 2014-07-17

Family

ID=40952720

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97072359T PT2252312E (pt) 2008-02-07 2009-02-06 Métodos de prevenção ou tratamento de resistência a insulina

Country Status (12)

Country Link
US (7) US8088727B2 (pt)
EP (7) EP3272353A1 (pt)
JP (6) JP5453320B2 (pt)
CN (2) CN101939019B (pt)
CA (1) CA2713150C (pt)
CY (1) CY1115305T1 (pt)
DK (1) DK2252312T3 (pt)
ES (1) ES2458870T3 (pt)
PL (1) PL2252312T3 (pt)
PT (1) PT2252312E (pt)
SI (1) SI2252312T1 (pt)
WO (1) WO2009100363A2 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3167935B1 (en) 2003-05-01 2018-07-18 Cornell Research Foundation, Inc. Method and carrier complexes for delivering molecules to cells
CA2622911C (en) * 2005-09-16 2016-12-06 Cornell Research Foundation, Inc. Methods for reducing cd36 expression
ES2458870T3 (es) * 2008-02-07 2014-05-07 Cornell University Procedimientos para prevenir o tratar la resistencia a la insulina
EP2408463B1 (en) * 2009-03-20 2016-10-19 The General Hospital Corporation d/b/a Massachusetts General Hospital D-arg-2'6'-dimethyltyrosine-lys-phe-nh2 for use in the prevention and treatment of burn injuries and secondary complications
CN107412724A (zh) * 2009-08-12 2017-12-01 康奈尔大学 预防或治疗代谢综合症的方法
PT3708178T (pt) 2009-08-24 2023-11-16 Stealth Biotherapeutics Inc Peptídeo para uso ao prevenir ou tratar a degeneração macular
EP2944317A1 (en) * 2009-10-05 2015-11-18 Cornell University Methods for the prevention or treatment of heart failure
WO2011082328A1 (en) * 2009-12-31 2011-07-07 Stealth Peptides International, Inc. Methods for performing a coronary artery bypass graft procedure
JP2013518057A (ja) * 2010-01-25 2013-05-20 コーネル ユニヴァーシティー 芳香族カチオン性ペプチドおよびその使用
US8956859B1 (en) 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
GB201018125D0 (en) * 2010-10-26 2010-12-08 Marealis As Peptide
EP3009141A1 (en) * 2011-12-09 2016-04-20 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
CN105343869A (zh) * 2012-02-22 2016-02-24 康德生物医疗技术公司 用于预防或治疗眼科病状的方法和组合物
AU2013237827B2 (en) * 2012-03-30 2017-12-14 Stealth Biotherapeutics Inc. Methods and compositions for the prevention and treatment neuropathy
CA2880648A1 (en) * 2012-08-02 2014-02-06 Stealth Peptides International, Inc. Methods for treatment of atherosclerosis
JP2016506391A (ja) * 2012-12-06 2016-03-03 ステルス ペプチドズ インターナショナル インコーポレイテッド ペプチド治療薬およびその使用方法
AU2017324510B2 (en) 2016-09-07 2023-08-31 Temple University - Of The Commonwealth System Of Higher Education Compositions and methods for treatment of insulin resistance
BR112020018010A2 (pt) 2018-03-07 2020-12-29 Temple University - Of The Commonwealth System Of Higher Education Métodos de prevenção ou tratamento de diabetes tipo 2, de prevenção ou tratamento de pré-diabetes e de prevenção ou tratamento de uma condição em um indivíduo em necessidade
US20200392075A1 (en) * 2018-03-07 2020-12-17 Temple University - Of The Commonwealth System Of Higher Education Compositions and methods for treatment of insulin resistance
CA3191819A1 (en) 2020-09-09 2022-03-17 Hazel Szeto Methods and compositions for delivery of biotin to mitochondria
US20240122884A1 (en) * 2022-10-03 2024-04-18 Transdermal Biotechnology, Inc. Systems and methods for delivery of n-lactoyl-phenylalanine and other n-lactoyl-amino acids

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5602100A (en) 1988-06-30 1997-02-11 Astra Ab Dermorphin analogs having pharmacological activity
ES2085865T3 (es) 1988-06-30 1996-06-16 Astra Ab Analogos de dermorfina, sus metodos de preparacion, composiciones farmaceuticas, y metodos de tratamiento terapeutico que los emplean.
US5674980A (en) 1989-12-21 1997-10-07 Biogen Inc Fusion protein comprising tat-derived transport moiety
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
IS4261A (is) 1994-02-21 1995-08-22 Astra Aktiebolag Nýir peptíð-ópíóíðar til meðhöndlunar á verkjum og notkun þeirra
DE69630918T2 (de) 1995-06-09 2004-10-28 Hisamitsu Pharmaceutical Co., Inc., Tosu Matrix für Iontophorese
US5849761A (en) 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
US5885958A (en) 1997-03-25 1999-03-23 Administrators Of The Tulane Educational Fund Mu-opiate receptor peptides
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6221355B1 (en) 1997-12-10 2001-04-24 Washington University Anti-pathogen system and methods of use thereof
US6268398B1 (en) 1998-04-24 2001-07-31 Mitokor Compounds and methods for treating mitochondria-associated diseases
CA2339218C (en) * 1998-07-31 2008-10-28 Mount Sinai Hospital Methods and compositions for increasing insulin sensitivity
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
SE9900961D0 (sv) 1999-03-16 1999-03-16 Astra Ab Novel compounds
JP2003511362A (ja) 1999-10-04 2003-03-25 ユニバーシティー オブ メディシン アンド デンティストリー オブ ニュー ジャージー 新規カルバメートおよび尿素類
US6759520B1 (en) 1999-10-28 2004-07-06 The New England Medical Center Hospitals, Inc. Chimeric analgesic peptides
US20050192215A1 (en) 2000-01-21 2005-09-01 Malabika Ghosh Methods and materials relating to novel polypeptides and polynucleotides
EP1303186B1 (en) 2000-07-18 2011-01-26 Cornell Research Foundation, Inc. Medicinal uses of mu-opioid receptor agonists
US6900178B2 (en) 2000-09-12 2005-05-31 University Of Kentucky Research Foundation Protection against ischemia and reperfusion injury
US20070015146A1 (en) 2001-05-22 2007-01-18 Gene Logic, Inc. Molecular nephrotoxicology modeling
EP2491943B1 (en) 2003-02-04 2018-10-10 Cornell Research Foundation, Inc. Methods for preventing mitochondrial permeability transition
EP3167935B1 (en) 2003-05-01 2018-07-18 Cornell Research Foundation, Inc. Method and carrier complexes for delivering molecules to cells
US7232824B2 (en) 2003-09-30 2007-06-19 Scios, Inc. Quinazoline derivatives as medicaments
RU2376028C2 (ru) 2004-01-23 2009-12-20 Корнелл Рисеч Фаундейшн, Инк. Способ уменьшения окислительного повреждения (варианты)
US20050272101A1 (en) 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
CA2622911C (en) * 2005-09-16 2016-12-06 Cornell Research Foundation, Inc. Methods for reducing cd36 expression
US20070259377A1 (en) * 2005-10-11 2007-11-08 Mickey Urdea Diabetes-associated markers and methods of use thereof
US20080027082A1 (en) 2006-06-19 2008-01-31 Berthold Hocher Use of adenosine a1 antagonists in radiocontrast media induced nephropathy
ES2458870T3 (es) * 2008-02-07 2014-05-07 Cornell University Procedimientos para prevenir o tratar la resistencia a la insulina

Also Published As

Publication number Publication date
JP2011511805A (ja) 2011-04-14
CA2713150A1 (en) 2009-08-13
JP2017052801A (ja) 2017-03-16
JP2014065738A (ja) 2014-04-17
SI2252312T1 (sl) 2014-08-29
US20170100450A1 (en) 2017-04-13
PL2252312T3 (pl) 2014-10-31
JP2015227353A (ja) 2015-12-17
US20190269749A1 (en) 2019-09-05
EP2902036A1 (en) 2015-08-05
DK2252312T3 (da) 2014-06-16
JP2019167384A (ja) 2019-10-03
CN104107417B (zh) 2017-04-12
JP5453320B2 (ja) 2014-03-26
EP2252312A4 (en) 2011-07-06
EP2712620A1 (en) 2014-04-02
CA2713150C (en) 2016-01-05
US20120149638A1 (en) 2012-06-14
JP2018090620A (ja) 2018-06-14
EP3622963A1 (en) 2020-03-18
US20130303447A1 (en) 2013-11-14
CN104107417A (zh) 2014-10-22
WO2009100363A3 (en) 2009-12-30
EP3441079A1 (en) 2019-02-13
CY1115305T1 (el) 2017-01-04
CN101939019B (zh) 2014-07-16
ES2458870T3 (es) 2014-05-07
US8088727B2 (en) 2012-01-03
EP2252312B1 (en) 2014-04-09
US20090253641A1 (en) 2009-10-08
EP3103467A1 (en) 2016-12-14
EP2252312A2 (en) 2010-11-24
US20150359839A1 (en) 2015-12-17
EP3272353A1 (en) 2018-01-24
WO2009100363A2 (en) 2009-08-13
US20180185435A1 (en) 2018-07-05
CN101939019A (zh) 2011-01-05

Similar Documents

Publication Publication Date Title
EP2252312A4 (en) METHOD FOR PREVENTING OR TREATING INSULIN RESISTANCE
IL257418A (en) Methods for treating addiction
HK1247820A1 (zh) 預防或治療代謝綜合症的方法
IL212348A0 (en) Treatment method
IL209895A (en) Compounds for the prevention and / or treatment of β-amyloidoses
PL2452709T3 (pl) Kaniula
IL205554A (en) An insulin resistance treatment containing melanocortin
HK1161275A1 (en) Halogen-stabilized insulin
SG11201401811WA (en) Method for preventing and/or treating insulin resistance
GB0802634D0 (en) Catheter
IL213619A0 (en) Treatment
GB0802116D0 (en) Treatment
EP2371415A4 (en) CATHETER
GB0822011D0 (en) Treatment
EP2341936A4 (en) METHOD FOR TREATING OR PREVENTING IL-1ß-CONTAINED ILLNESSES
GB2456425B (en) Catheter
PL2441462T3 (pl) Sposób leczenia cukrzycy typu I
GB0811992D0 (en) Treatment
HU0800419D0 (en) Catheter
HK1157690A1 (en) Syringe
GB0812019D0 (en) Insulin
GB0718684D0 (en) Treatment method
EP2254410A4 (en) PROCESS FOR INHIBITING THE REMOVAL OF MEDICINAL PRODUCTS
GB0820972D0 (en) Treatment
GB0805912D0 (en) Treatment